Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Hematol
Hauptverfasser: Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2017
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486779/
https://ncbi.nlm.nih.gov/pubmed/28456851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2994-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge